ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE

Pre-Launch

abacavir; dolutegravir; lamivudine

NDAORALTABLETPriority Review
Lifecycle
Pre-Launch

Mechanism of Action

fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].

Indications (2)

HIV-1 infection in adultsweighing at least 6 kg
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers